Top Story Today
AbbVie Bets $10.9 Billion on a Single Molecule to Outlast the Humira Hangover
AbbVie is acquiring Apogee Therapeutics for $10.9 billion in cash, a 49% premium, to get its hands on zumilokibart, an extended-half-life IL-13 antibody that could let patients dose once every three to six months instead of biweekly. It's a direct shot at Sanofi and Regeneron's Dupixent, which pulled in roughly $18 billion in revenue last year across atopic dermatitis and asthma. Wall Street is surprisingly on board (AbbVie's stock actually rose 4.6% on announcement day, the opposite of the usual buyer's remorse), but the deal won't add to earnings until 2032. Phase 3 trials don't even start until late 2026.
Why it matters: With Humira now contributing just 7-8% of revenue after biosimilar erosion, AbbVie is rebuilding its immunology franchise for the next decade. This deal reshapes the competitive landscape in a $14-17 billion atopic dermatitis market that's heading toward $30 billion by decade's end.
Read more →Deals and Discovery
Novartis Paid $1.1 Billion for a Drug That's Never Been in a Human
Novartis acquired UK-based Myricx Bio for $1.1 billion upfront (up to $1.5 billion total) to gain a completely novel ADC payload class that blocks an enzyme called NMT, essentially pulling the rug out from under dozens of cancer cell survival proteins simultaneously. No human data exists yet. In mice, the lead molecule outperformed the gold-standard HER2 ADC. If the clinic validates those results, Novartis gets a platform for building next-gen cancer therapies. If not, it'll be pharma's priciest preclinical flameout.
Read more →Novo Nordisk Gets EU Green Light for the First Oral GLP-1 Weight-Loss Pill
The European Commission approved Novo Nordisk's once-daily 25 mg Wegovy tablet, the first oral GLP-1 cleared for obesity in the EU. It delivered 13.6% average weight loss over 64 weeks, close to the injectable version's 15-17%. Roughly 20-30% of eligible patients have been avoiding GLP-1 therapy because of needles; this pill could unlock that entire population. The catch: you have to fast eight hours beforehand and wait 30 minutes after swallowing before eating anything.
Read more →Generic Ozempic Just Landed in South Africa
Sun Pharma won approval to sell generic semaglutide in South Africa after Novo Nordisk's core patent expired in March. It's only the second country with a cheaper alternative to Ozempic, and it signals the start of GLP-1 commoditization across emerging markets. Regulators in Brazil, Turkey, and Southeast Asia are watching closely.
Read more →Clinical and Regulatory
The FDA Just Invented a New Category of Cell Therapy
Orca Bio's Tregzi became the first-ever regulatory T-cell therapy to win FDA approval, doubling chronic graft-versus-host disease-free survival (78% vs. 38%) in transplant patients. At $428,000, it's pricey, but chronic GVHD costs years of immunosuppression and hospitalizations. The approval validates an entire therapeutic class; over 50 companies with Treg programs just got a massive de-risking event.
Read more →Sobi's Gout Drug Aced Its Trials. The FDA Still Said No.
Sobi got a complete response letter for its gout therapy NASP, and the reason wasn't safety or efficacy. It was factory problems. Roughly 74% of FDA rejection letters now cite manufacturing deficiencies, making the factory floor the hardest exam in drug development. Resubmission could take 6 to 12 months.
Read more →The Eye Was Supposed to Be Gene Therapy's Easy Win. J&J Struck Out Twice.
J&J killed its geographic atrophy gene therapy after the Phase 2b PARASOL trial disappointed, marking its second ocular gene therapy failure in a year. The eye has long been considered the most favorable organ for gene delivery. A growing list of failures from Biogen, Novartis, and now J&J suggests Luxturna was lightning in a bottle, not a roadmap.
Read more →Crisis Watch
Two Deaths, a Black Box, and 500 Pink Slips at Sarepta
Two pediatric Duchenne patients died of liver failure after receiving Sarepta's gene therapy Elevidys, earning it the FDA's most severe black box warning. The agency also yanked the non-ambulatory indication entirely. Sarepta responded by cutting 36% of its workforce (500 people) and pivoting away from gene therapy toward siRNA, a dramatic U-turn for the company that built its identity on the technology.
Read more →The Only Drug That Prevents Congenital Syphilis Just Got Recalled
Pfizer recalled Bicillin L-A, the sole FDA-approved penicillin injection for treating syphilis in pregnant patients, after floating particles were found in prefilled syringes. There is no proven alternative for pregnant women, and congenital syphilis cases have surged 700% since 2015. Remaining supply is being rationed strictly for pregnant patients and newborns, with full domestic supply expected to recover by Q4 2026 for adult prefilled syringes, though some presentations may take longer.
Read more →Sanofi Got Caught Trash-Talking a Rival Vaccine
The European Commission opened a formal antitrust investigation into Sanofi for allegedly running a misleading campaign that trashed CSL Seqirus's flu vaccine Fluad to protect its own market dominance. Sanofi has already offered commitments to settle, which is the corporate equivalent of plea-bargaining before trial. If the EU's theory holds, it could constrain how every dominant pharma company markets against competitors.
Read more →